Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

298.62 +0.12 (+0.04%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,679,406
Open 297.61
Bid (Size) 298.32 (1)
Ask (Size) 301.00 (1)
Prev. Close 298.50
Today's Range 295.90 - 299.74
52wk Range 218.44 - 329.72
Shares Outstanding N/A
Dividend Yield 2.85%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Expert Ratings For Amgen
Via Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
The companies are closing in on the finish line for two new COPD treatments. 
Via Investor's Business Daily

Performance

YTD
+0.41%
+0.41%
1 Month
-4.11%
-4.11%
3 Month
+9.97%
+9.97%
6 Month
+8.07%
+8.07%
1 Year
+34.34%
+34.34%

More News

Read More
3 Stocks to Buy as Ozempic Surges in Popularity
Via InvestorPlace
Decoding Amgen's Options Activity: What's the Big Picture?
Via Benzinga
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
Via Investor's Business Daily
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Via Benzinga
Where Will Amgen Be in 3 Years?
Via The Motley Fool
Is Geron Stock a Buy Following Its First New Drug Approval?
Via The Motley Fool
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Via Benzinga
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Via The Motley Fool
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Via Benzinga
Exposures Product Safety
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Via Benzinga
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Via The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Via Benzinga
Exposures Product Safety
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
7 Reliable Blue-Chip Stocks That Cannot Miss
Via InvestorPlace
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Via InvestorPlace
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.